Author | Brian Miller, MD, PhD, MPH

Articles

Understanding Comorbid Insomnia and Alcohol Use

August 07, 2020

Article

Clinical considerations for evaluating treatment options for patients with insomnia and AUD versus patients with primary insomnia without substance use comorbidity.

Novel Insights on Cannabis and Psychosis

July 28, 2020

Article

There is evidence in both patients with psychotic disorders and the general population that cannabis use is associated with adverse effects of psychopathology and cognition.

Autoimmune Psychosis?

July 13, 2020

Article

New research on the prevalence of NMDA-receptor antibody encephalitis in first-episode and treatment-resistant psychosis

Does Insomnia Predict the Onset of Mental Illness?

July 11, 2020

Article

Because insomnia is a syndrome marked by chronic sleep onset and/or continuity problems associated with impaired daytime functioning, it is important that clinicians screen for sleep issues in their patients.

Lowering Prolactin Levels in Patients With Psychosis

July 10, 2020

Article

Treatment strategies for antipsychotic-induced hyperprolactinemia.

The Need for Speed

June 04, 2020

Article

Psychomotor speed may be a relevant target in studies of the immune system and its impact on the brain in patients with schizophrenia.

Is Esketamine Augmentation a Win for Depression?

June 04, 2020

Article

Last year, the FDA approved esketamine, a rapidly acting adjunctive intranasal therapy for treatment-resistant depression. Now, researchers are exploring its efficacy in major depressive disorder.

Getting the Dose Just Right

June 04, 2020

Article

There is inadequate information regarding optimal antipsychotic doses in the treatment of acute schizophrenia that balance efficacy and safety. This article helps you get it right.

What's In Your Mouth?

May 09, 2020

Article

The role of the oropharyngeal microbiome in schizophrenia and mania.

Clozapine for The Ages?

May 08, 2020

Article

New (and not-so-new) insights on antipsychotics across a range of different measures of treatment response.